Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer.

Zhang H, Liu T, Zhang Z, Payne SH, Zhang B, McDermott JE, Zhou JY, Petyuk VA, Chen L, Ray D, Sun S, Yang F, Chen L, Wang J, Shah P, Cha SW, Aiyetan P, Woo S, Tian Y, Gritsenko MA, Clauss TR, Choi C, Monroe ME, Thomas S, Nie S, Wu C, Moore RJ, Yu KH, Tabb DL, Fenyö D, Bafna V, Wang Y, Rodriguez H, Boja ES, Hiltke T, Rivers RC, Sokoll L, Zhu H, Shih IM, Cope L, Pandey A, Zhang B, Snyder MP, Levine DA, Smith RD, Chan DW, Rodland KD; CPTAC Investigators.

Cell. 2016 Jul 28;166(3):755-765. doi: 10.1016/j.cell.2016.05.069. Epub 2016 Jun 29.

2.

Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome.

Wang ZC, Birkbak NJ, Culhane AC, Drapkin R, Fatima A, Tian R, Schwede M, Alsop K, Daniels KE, Piao H, Liu J, Etemadmoghadam D, Miron A, Salvesen HB, Mitchell G, DeFazio A, Quackenbush J, Berkowitz RS, Iglehart JD, Bowtell DD; Australian Ovarian Cancer Study Group, Matulonis UA.

Clin Cancer Res. 2012 Oct 15;18(20):5806-15. doi: 10.1158/1078-0432.CCR-12-0857. Epub 2012 Aug 21.

3.

Targeted Proteomic Analyses of Histone H4 Acetylation Changes Associated with Homologous-Recombination-Deficient High-Grade Serous Ovarian Carcinomas.

Thomas SN, Chen L, Liu Y, Höti N, Zhang H.

J Proteome Res. 2017 Oct 6;16(10):3704-3710. doi: 10.1021/acs.jproteome.7b00405. Epub 2017 Sep 14.

4.

Morphologic correlates of molecular alterations in extrauterine Müllerian carcinomas.

Ritterhouse LL, Nowak JA, Strickland KC, Garcia EP, Jia Y, Lindeman NI, Macconaill LE, Konstantinopoulos PA, Matulonis UA, Liu J, Berkowitz RS, Nucci MR, Crum CP, Sholl LM, Howitt BE.

Mod Pathol. 2016 Aug;29(8):893-903. doi: 10.1038/modpathol.2016.82. Epub 2016 May 6.

5.

A BRCA1/2 Mutational Signature and Survival in Ovarian High-Grade Serous Carcinoma.

Dong F, Davineni PK, Howitt BE, Beck AH.

Cancer Epidemiol Biomarkers Prev. 2016 Nov;25(11):1511-1516. Epub 2016 Aug 5.

6.

Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.

Vang R, Levine DA, Soslow RA, Zaloudek C, Shih IeM, Kurman RJ.

Int J Gynecol Pathol. 2016 Jan;35(1):48-55. doi: 10.1097/PGP.0000000000000207.

7.

High level of chromosomal aberration in ovarian cancer genome correlates with poor clinical outcome.

Cope L, Wu RC, Shih IeM, Wang TL.

Gynecol Oncol. 2013 Mar;128(3):500-5. doi: 10.1016/j.ygyno.2012.11.031. Epub 2012 Nov 28.

8.

A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development.

Sherman-Baust CA, Kuhn E, Valle BL, Shih IeM, Kurman RJ, Wang TL, Amano T, Ko MS, Miyoshi I, Araki Y, Lehrmann E, Zhang Y, Becker KG, Morin PJ.

J Pathol. 2014 Jul;233(3):228-37. doi: 10.1002/path.4353.

9.

Integrated analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade serous ovarian carcinoma.

Creighton CJ, Hernandez-Herrera A, Jacobsen A, Levine DA, Mankoo P, Schultz N, Du Y, Zhang Y, Larsson E, Sheridan R, Xiao W, Spellman PT, Getz G, Wheeler DA, Perou CM, Gibbs RA, Sander C, Hayes DN, Gunaratne PH; Cancer Genome Atlas Research Network.

PLoS One. 2012;7(3):e34546. doi: 10.1371/journal.pone.0034546. Epub 2012 Mar 29.

10.

Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes.

McBride DJ, Etemadmoghadam D, Cooke SL, Alsop K, George J, Butler A, Cho J, Galappaththige D, Greenman C, Howarth KD, Lau KW, Ng CK, Raine K, Teague J, Wedge DC, Cancer Study Group AO, Caubit X, Stratton MR, Brenton JD, Campbell PJ, Futreal PA, Bowtell DD.

J Pathol. 2012 Aug;227(4):446-55. doi: 10.1002/path.4042. Epub 2012 Jul 2.

11.

Similar protein expression profiles of ovarian and endometrial high-grade serous carcinomas.

Hiramatsu K, Yoshino K, Serada S, Yoshihara K, Hori Y, Fujimoto M, Matsuzaki S, Egawa-Takata T, Kobayashi E, Ueda Y, Morii E, Enomoto T, Naka T, Kimura T.

Br J Cancer. 2016 Mar 1;114(5):554-61. doi: 10.1038/bjc.2016.27. Epub 2016 Feb 18.

12.

The gene copy number of c-MET has a significant impact on progression-free survival in Korean patients with ovarian carcinoma.

Kim WY, Shim SH, Jung HY, Dong M, Kim SN, Lee SJ.

Hum Pathol. 2017 Jun;64:98-105. doi: 10.1016/j.humpath.2017.04.002. Epub 2017 Apr 17.

PMID:
28428108
13.

Amplification of the ch19p13.2 NACC1 locus in ovarian high-grade serous carcinoma.

Shih IeM, Nakayama K, Wu G, Nakayama N, Zhang J, Wang TL.

Mod Pathol. 2011 May;24(5):638-45. doi: 10.1038/modpathol.2010.230. Epub 2011 Jan 14.

14.

Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas.

Kuo KT, Guan B, Feng Y, Mao TL, Chen X, Jinawath N, Wang Y, Kurman RJ, Shih IeM, Wang TL.

Cancer Res. 2009 May 1;69(9):4036-42. doi: 10.1158/0008-5472.CAN-08-3913. Epub 2009 Apr 21. Erratum in: Cancer Res. 2009 Jun 15;69(12):5267.

15.

Distinct homologous recombination gene expression profiles after neoadjuvant chemotherapy associated with clinical outcome in patients with ovarian cancer.

Kessous R, Octeau D, Klein K, Tonin PN, Greenwood CMT, Pelmus M, Laskov I, Kogan L, Salvador S, Lau S, Yasmeen A, Gotlieb WH.

Gynecol Oncol. 2018 Mar;148(3):553-558. doi: 10.1016/j.ygyno.2018.01.017. Epub 2018 Feb 1.

PMID:
29395310
16.

Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma.

Salvador S, Rempel A, Soslow RA, Gilks B, Huntsman D, Miller D.

Gynecol Oncol. 2008 Sep;110(3):408-17. doi: 10.1016/j.ygyno.2008.05.010. Epub 2008 Jul 1.

PMID:
18597838
17.

Molecular genetics of ovarian carcinomas.

Diebold J.

Histol Histopathol. 1999 Jan;14(1):269-77. doi: 10.14670/HH-14.269. Review.

PMID:
9987671
18.

Identification of multiple novel protein biomarkers shed by human serous ovarian tumors into the blood of immunocompromised mice and verified in patient sera.

Beer LA, Wang H, Tang HY, Cao Z, Chang-Wong T, Tanyi JL, Zhang R, Liu Q, Speicher DW.

PLoS One. 2013;8(3):e60129. doi: 10.1371/journal.pone.0060129. Epub 2013 Mar 27.

19.

Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.

Liu Y, Yasukawa M, Chen K, Hu L, Broaddus RR, Ding L, Mardis ER, Spellman P, Levine DA, Mills GB, Shmulevich I, Sood AK, Zhang W.

JAMA Oncol. 2015 Jul;1(4):486-94. doi: 10.1001/jamaoncol.2015.1432.

20.

Analysis and comparison of somatic mutations in paired primary and recurrent epithelial ovarian cancer samples.

Kim YM, Lee SW, Chun SM, Kim DY, Kim JH, Kim KR, Kim YT, Nam JH, van Hummelen P, MacConaill LE, Hahn WC, Jang SJ.

PLoS One. 2014 Jun 17;9(6):e99451. doi: 10.1371/journal.pone.0099451. eCollection 2014.

Supplemental Content

Support Center